MedChemExpress

Osimertinib

#HY-15772

27
Citing papers
381
Combined citations
Supplier page Find this product

Research areas

Lung Cancer Treatments and Mutations8HER2/EGFR in Cancer Research4Protein Degradation and Inhibitors3Cancer, Hypoxia, and Metabolism3Cancer Mechanisms and Therapy2Cancer-related gene regulation2Computational Drug Discovery Methods2Cancer Genomics and Diagnostics2

Papers citing this product

1
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Journal of Experimental & Clinical Cancer Research·2019·85 cit.·DOI
2
MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling
Cell Death and Disease·2019·50 cit.·DOI
3
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma
Cancer Communications·2023·48 cit.·DOI
4
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop
Oncogene·2025·36 cit.·DOI
5
Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer
Frontiers in Molecular Biosciences·2021·28 cit.·DOI
6
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Molecular Cancer Therapeutics·2023·24 cit.·DOI
7
Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation
Cancers·2021·17 cit.·DOI
8
A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer
Communications Biology·2021·17 cit.·DOI
9
Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
Cancer Cell International·2021·15 cit.·DOI
10
Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer
Cell Death and Disease·2025·11 cit.·DOI

Similar products

ProductVendorPricePapers
WZ4002MedChemExpress—92
NaquotinibMedChemExpress—76
RociletinibMedChemExpress—1
OlmutinibMedChemExpress——